Perspective Therapeutics (CATX) 10-Q 10 Nov 21 2022 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Sep. 30, 2021	Nov. 09, 2021
Document Information [Line Items]
Entity Central Index Key	0000728387
Entity Registrant Name	IsoRay, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-33407
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	41-1458152
Entity Address, Address Line One	350 Hills St., Suite 106
Entity Address, City or Town	Richland
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	99354
City Area Code	509
Local Phone Number	375-1202
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	ISR
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		141,915,266

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2021	Jun. 30, 2021
Current assets:
Cash and cash equivalents	$ 61,690	$ 63,828
Accounts receivable, net	1,902	2,013
Inventory	1,060	980
Prepaid expenses and other current assets	306	481
Total current assets	64,958	67,302
Property and equipment, net	1,953	1,958
Right of use asset, net (Note 8)	705	768
Restricted cash	182	182
Inventory, non-current	792	76
Other assets, net	120	130
Total assets	68,710	70,416
Current liabilities:
Accounts payable and accrued expenses	768	730
Lease liability (Note 8)	256	252
Accrued protocol expense	120	98
Accrued radioactive waste disposal	102	100
Accrued payroll and related taxes	300	362
Accrued vacation	253	259
Total current liabilities	1,799	1,801
Non-current liabilities:
Lease liability, non-current (Note 8)	459	524
Accrued payroll and related taxes, non-current	77	77
Asset retirement obligation	616	608
Total liabilities	2,951	3,010
Commitments and contingencies (Note 7)
Stockholders' equity:
Common stock, $.001 par value; 200,000,000 shares authorized; 141,915,266 and 141,915,266 shares issued and outstanding	142	142
Additional paid-in capital	159,185	158,589
Accumulated deficit	(93,568)	(91,325)
Total stockholders' equity	65,759	67,406
Series B Preferred Stock [Member]
Stockholders' equity:
Total liabilities and stockholders' equity	$ 68,710	$ 70,416

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2021	Jun. 30, 2021
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	141,915,266	141,915,266
Common stock, shares outstanding (in shares)	141,915,266	141,915,266

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Sales, net	$ 2,564	$ 2,384
Cost of sales	1,535	1,138
Gross profit	1,029	1,246
Operating expenses:
Research and development	702	312
Sales and marketing	761	581
General and administrative	1,840	1,067
Total operating expenses	3,303	1,960
Operating loss	(2,274)	(714)
Non-operating income:
Interest income, net	31	1
Non-operating income, net	31	1
Net loss	(2,243)	(713)
Preferred stock dividends	0	(3)
Net loss applicable to common stockholders	$ (2,243)	$ (716)
Basic and diluted loss per share (in dollars per share)	$ (0.02)	$ (0.01)
Weighted average shares used in computing net loss per share:
Basic and diluted (in shares)	141,915	68,898

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,243)	$ (713)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation expense	59	34
Amortization of other assets	10	10
Accretion of asset retirement obligation	8	8
Share-based compensation	596	85
Changes in operating assets and liabilities:
Accounts receivable, net	111	286
Inventory	(796)	(63)
Prepaid expenses and other current assets	175	18
Accounts payable and accrued expenses	40	106
Accrued protocol expense	22	56
Accrued radioactive waste disposal	2	6
Accrued payroll and related taxes	(62)	(189)
Accrued vacation	(6)	18
Net cash used by operating activities	(2,084)	(338)
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment	(54)	(113)
Net cash used by investing activities	(54)	(113)
Net decrease in cash, cash equivalents, and restricted cash	(2,138)	(451)
Cash, cash equivalents, and restricted cash beginning of quarter	64,010	2,573	$ 2,573
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH END OF QUARTER	61,872	2,122	64,010
Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets:
Cash and cash equivalents	61,690	1,940	63,828
Restricted cash	182	182	$ 182
Total cash, cash equivalents, and restricted cash shown on the consolidated statements of cashflows	$ 61,872	$ 2,122

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member]Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balances (in shares) at Jun. 30, 2020	59,065	68,897,779
Balances at Jun. 30, 2020	$ 0	$ 69	$ 93,592	$ (87,938)	$ 5,723
Share-based compensation			85		85
Net loss				(713)	(713)
Balances (in shares) at Sep. 30, 2020	59,065	68,897,779
Balances at Sep. 30, 2020	$ 0	$ 69	93,677	(88,651)	5,095
Balances (in shares) at Jun. 30, 2021	0	141,915,266
Balances at Jun. 30, 2021	$ 0	$ 142	158,589	(91,325)	67,406
Share-based compensation			596		596
Net loss				(2,243)	(2,243)
Balances (in shares) at Sep. 30, 2021	0	141,915,266
Balances at Sep. 30, 2021	$ 0	$ 142	$ 159,185	$ (93,568)	$ 65,759

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation	3 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	1. Basis of Presentation The accompanying unaudited interim consolidated financial statements are those of Isoray, Inc., and its wholly-owned subsidiaries, referred to herein as “Isoray” or the “Company”. All significant intercompany accounts and transactions have been eliminated in the consolidation. In the opinion of management, all adjustments necessary for the fair presentation of the consolidated financial statements have been included. These unaudited interim consolidated financial statements should be read in conjunction with our audited consolidated financial statements and related notes as set forth in the Company’s annual report filed on Form 10 June 30, 2021. The unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP) have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures are adequate for the information not The Company anticipates that as the result of continuing operating losses and the significant net operating losses available from prior fiscal years, its effective income tax rate for fiscal year 2022

Note 2 - New Accounting Standar

Note 2 - New Accounting Standards	3 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Accounting Standards Update and Change in Accounting Principle [Text Block]	2. New Accounting Standards Accounting Standards Updates to Become Effective in Future Periods Accounting standards that have been issued or proposed by the Financial Accounting Standards Board or “FASB” that do not not not not

Note 3 - Loss Per Share

Note 3 - Loss Per Share	3 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	3. Loss per Share Basic and diluted earnings (loss) per share are calculated by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding and does not 30, 2021 2020, not Securities not 30, 2021 2020, September 30, 2021 2020 Series B preferred stock - 59 Common stock warrants 2,646 6,080 Common stock options 7,326 5,533 Total potential dilutive securities 9,972 11,672

Note 4 - Inventory

Note 4 - Inventory	3 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Inventory Disclosure [Text Block]	4. Inventory Inventory consisted of the following at September 30, 2021 June 30, 2021 ( September 30, June 30, 2021 2021 Raw materials $ 757 $ 645 Work in process 268 286 Finished goods 35 49 Total inventory, current $ 1,060 $ 980 September 31, June 30, 2021 2021 Enriched barium, non-current $ 720 $ - Raw materials, non-current 72 76 Total inventory, non-current $ 792 $ 76 Inventory, non-current represents raw materials that were ordered in quantities to obtain volume cost discounts which based on current and anticipated sales volumes will not August 25, 2017, 130 June 30, 2021, 894 On September 9, 2021, September 2021 6000 September 2021, 131, three September 30, 2021, not 131 September 30, 2021, 5,894 894 twelve 5,000 September 30, 2022. no third 131

Note 5 - Property and Equipment

Note 5 - Property and Equipment	3 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property and Equipment Property and equipment consisted of the following at September 30, 2021 June 30, 2021 ( September 30, June 30, 2021 2021 Land $ 366 $ 366 Equipment 4,305 4,202 Leasehold improvements 4,143 4,143 Other 1 445 495 Property and equipment 9,259 9,206 Less accumulated depreciation (7,306 ) (7,248 ) Property and equipment, net $ 1,953 $ 1,958 1 not September 30, 2021 June 30, 2021 $207,000. 2017. three five

Note 6 - Share-based Compensati

Note 6 - Share-based Compensation	3 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	6. Share-Based Compensation The weighted average fair value of stock option awards granted and the key assumptions used in the Black-Scholes valuation model to calculate the fair value are as follows: For the Three Months Ended September 30, 2021 2020 Weighted average fair value $0.58 $0.46 Options issued 2,951,600 40,000 Exercise price $0.69 to $0.79 $0.64 to $0.74 Expected term (in years) 5 5 Risk-free rate 0.73% to 0.89% 0.22% to 0.29% Volatility 99% 83% The following table presents the share-based compensation expense recognized for stock-based options during the three 30, 2021 2020 Three Months 2021 2020 Cost of sales $ 44 $ 2 Research and development expenses 130 12 Sales and marketing expenses 49 18 General and administrative expenses 373 53 Total share-based compensation $ 596 $ 85 As of September 30, 2021, 1 .31 A summary of stock options within the Company’s share-based compensation plans as of September 30, 2021 Weighted Weighted Average Number of Exercise Contractual Intrinsic As of September 30, 2021 Options Price Term (Years) Value Outstanding 7,326 $ .72 8.08 $ 343 Vested and expected to vest 7,326 $ .72 8.08 $ 343 Vested and exercisable 4,205 $ .68 7.07 $ 289 There were no stock options exercised during the three September 30, 2021 2020, There were 2,951,600 and 40,000 option awards granted with a fair value of approximately $1,712,000 and $18,000, during the three September 30, 2021 2020, There were 7,500 and 2,000 stock option awards which expired during the three September 30, 2021 2020, There were 132,500 and 2,500 stock option awards forfeited during the three September 30, 2021 2020,

Note 7 - Commitments and Contin

Note 7 - Commitments and Contingencies	3 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	7. Commitments and Contingencies Isotope Purchase Agreement On August 26, 2020, August 2020 December 2021 131 February 10, 2021, March 18, 2021, 131 March 18, 2021 March 31, 2023. July 29, 2021, 131 August 19, 2021, 131

Note 8 - Leases

Note 8 - Leases	3 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	8. Leases For the three September 30, 2021 2020 three September 30, 2021 2020 September 30, 2021 6% The following table presents the future operating lease payments and lease liability included on the consolidated balance sheet related to the Company’s operating lease as of September 30, 2021 ( Year Ending June 30, 2022 (remaining nine months) 219 2023 292 2024 264 Total 775 Less: imputed interest (60 ) Total lease liability 715 Less current portion (256 ) Non-current lease liability $ 459

Note 9 - Contracts With Custome

Note 9 - Contracts With Customers	3 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	9. Contracts with Customers Sources of Revenue We have identified the following revenues disaggregated by revenue source: 1. Domestic – direct sales of products and services. 2. International – direct sales of products and services. During the three September 30, 2021 2020 no three September 30, 2021, not three September 30, 2020. Concentration of Customers The following are the Company's top customers, facilities, or physician practices that utilize multiple surgical facilities shown as a percentage of total sales: Three Months Ended September 30, Facility 2021 % of total revenue 2020 % of total revenue El Camino, Los Gatos, & other facilities 28.5 % 25.7 % GT Medical Technologies 15.0 % <10.0 % As of September 30, 2021 and 2020 respectively, no individual customers, or facilities, or physician practices made up greater than 10% of our accounts receivable.

Note 3 - Loss Per Share (Tables

Note 3 - Loss Per Share (Tables)	3 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	September 30, 2021 2020 Series B preferred stock - 59 Common stock warrants 2,646 6,080 Common stock options 7,326 5,533 Total potential dilutive securities 9,972 11,672

Note 4 - Inventory (Tables)

Note 4 - Inventory (Tables)	3 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, June 30, 2021 2021 Raw materials $ 757 $ 645 Work in process 268 286 Finished goods 35 49 Total inventory, current $ 1,060 $ 980
Schedule of Inventory, Noncurrent [Table Text Block]	September 31, June 30, 2021 2021 Enriched barium, non-current $ 720 $ - Raw materials, non-current 72 76 Total inventory, non-current $ 792 $ 76

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment (Tables)	3 Months Ended
	Sep. 30, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	September 30, June 30, 2021 2021 Land $ 366 $ 366 Equipment 4,305 4,202 Leasehold improvements 4,143 4,143 Other 1 445 495 Property and equipment 9,259 9,206 Less accumulated depreciation (7,306 ) (7,248 ) Property and equipment, net $ 1,953 $ 1,958

Note 6 - Share-based Compensa_2

Note 6 - Share-based Compensation (Tables)	3 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	For the Three Months Ended September 30, 2021 2020 Weighted average fair value $0.58 $0.46 Options issued 2,951,600 40,000 Exercise price $0.69 to $0.79 $0.64 to $0.74 Expected term (in years) 5 5 Risk-free rate 0.73% to 0.89% 0.22% to 0.29% Volatility 99% 83%
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months 2021 2020 Cost of sales $ 44 $ 2 Research and development expenses 130 12 Sales and marketing expenses 49 18 General and administrative expenses 373 53 Total share-based compensation $ 596 $ 85
Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]	Weighted Weighted Average Number of Exercise Contractual Intrinsic As of September 30, 2021 Options Price Term (Years) Value Outstanding 7,326 $ .72 8.08 $ 343 Vested and expected to vest 7,326 $ .72 8.08 $ 343 Vested and exercisable 4,205 $ .68 7.07 $ 289

Note 8 - Leases (Tables)

Note 8 - Leases (Tables)	3 Months Ended
	Sep. 30, 2021
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year Ending June 30, 2022 (remaining nine months) 219 2023 292 2024 264 Total 775 Less: imputed interest (60 ) Total lease liability 715 Less current portion (256 ) Non-current lease liability $ 459

Note 9 - Contracts With Custo_2

Note 9 - Contracts With Customers (Tables)	3 Months Ended
	Sep. 30, 2021
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Three Months Ended September 30, Facility 2021 % of total revenue 2020 % of total revenue El Camino, Los Gatos, & other facilities 28.5 % 25.7 % GT Medical Technologies 15.0 % <10.0 % As of September 30, 2021 and 2020 respectively, no individual customers, or facilities, or physician practices made up greater than 10% of our accounts receivable.

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation (Details Textual) Pure in Thousands	3 Months Ended
	Sep. 30, 2021
Effective Income Tax Rate Reconciliation, Percent, Total	0.00%

Note 3 - Loss Per Share - Antid

Note 3 - Loss Per Share - Antidilutive Securities (Details) - shares shares in Thousands	3 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Antidilutive securities (in shares)	9,972	11,672
Series B Preferred Stock [Member]
Antidilutive securities (in shares)	0	59
Warrant [Member]
Antidilutive securities (in shares)	2,646	6,080
Share-based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	7,326	5,533

Note 4 - Inventory (Details Tex

Note 4 - Inventory (Details Textual)	Sep. 09, 2021USD ($)
Enriched Barium Inventory [Member]
Payments to Suppliers	$ 720,000

Note 4 - Inventory - Current In

Note 4 - Inventory - Current Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Jun. 30, 2021
Raw materials	$ 757	$ 645
Work in process	268	286
Finished goods	35	49
Total inventory, current	$ 1,060	$ 980

Note 4 - Inventory - Noncurrent

Note 4 - Inventory - Noncurrent Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Jun. 30, 2021
Total inventory, non-current	$ 792	$ 76
Enriched Barium Inventory [Member]
Total inventory, non-current	720	0
Raw Materials [Member]
Total inventory, non-current	$ 72	$ 76

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2021
Depreciation, Total	$ 59,000	$ 34,000
Other [Member]
Depreciation, Total	0		$ 0
Construction in Progress [Member]
Capitalized Costs Related to Advance Planning and Design Work	$ 207,000		$ 207,000

Note 5 - Property and Equipme_4

Note 5 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands		Sep. 30, 2021	Jun. 30, 2021
Property and equipment, gross		$ 9,259	$ 9,206
Less accumulated depreciation		(7,306)	(7,248)
Property and equipment, net		1,953	1,958
Land [Member]
Property and equipment, gross		366	366
Equipment [Member]
Property and equipment, gross		4,305	4,202
Leasehold Improvements [Member]
Property and equipment, gross		4,143	4,143
Other [Member]
Property and equipment, gross	[1]	$ 445	$ 495
[1]	Plant and equipment, not placed in service are items that meet the capitalization threshold or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheet, and therefore, no depreciation expense has been recognized. Also included at September 30, 2021 and June 30, 2021 are costs associated with advance planning and design work on the Company’s new production facility of approximately $207,000. The advance planning and design work was primarily incurred in fiscal year 2017. The new production facility is currently on hold as the Company has sufficient production capacity to meet future demands and while the Company focuses its resources on revenue growth. It is anticipated that the Company will continue work on the new production facility in the next three to five years.

Note 6 - Share-based Compensa_3

Note 6 - Share-based Compensation (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 1,572,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	1 year 3 months 21 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)	0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	2,951,600	40,000
Share-based Compensation Arrangement By Share-based Payment Award Options Grants in Period Fair Value	$ 1,712,000	$ 18,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period (in shares)	7,500	2,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period (in shares)	132,500	2,500

Note 6 - Share-based Compensa_4

Note 6 - Share-based Compensation - Assumptions (Details) - $ / shares	3 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Weighted average fair value (in dollars per share)	$ 0.58	$ 0.46
Options issued (in shares)	2,951,600	40,000
Expected term (in years) (Year)	5 years	5 years
Volatility	99.00%	83.00%
Minimum [Member]
Exercise price (in dollars per share)	$ 0.69	$ 0.64
Risk-free rate	0.73%	0.22%
Maximum [Member]
Exercise price (in dollars per share)	$ 0.79	$ 0.74
Risk-free rate	0.89%	0.29%

Note 6 - Share-based Compensa_5

Note 6 - Share-based Compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Share-based compensation	$ 596	$ 85
Cost of Sales [Member]
Share-based compensation	44	2
Research and Development Expense [Member]
Share-based compensation	130	12
Selling and Marketing Expense [Member]
Share-based compensation	49	18
General and Administrative Expense [Member]
Share-based compensation	$ 373	$ 53

Note 6 - Share-based Compensa_6

Note 6 - Share-based Compensation - Summary of Stock Options (Details) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares
Outstanding (in shares) | shares	7,326
Outstanding, weighted exercise price (in dollars per share) | $ / shares	$ 0.72
Outstanding, weighted average contractual term (Year)	8 years 29 days
Outstanding, intrinsic value | $	$ 343
Vested and expected to vest, Options (in shares) | shares	7,326
Vested and expected to vest, weighted exercise price (in dollars per share) | $ / shares	$ 0.72
Vested and expected to vest, weighted average contractual term (Year)	8 years 29 days
Vested and expected to vest, intrinsic value | $	$ 343
Vested and exercisable (in shares) | shares	4,205
Vested and exercisable, weighted exercise price (in dollars per share) | $ / shares	$ 0.68
Vested and exercisable, weighted average contractual term (Year)	7 years 25 days
Vested and exercisable, intrinsic value | $	$ 289

Note 8 - Leases (Details Textua

Note 8 - Leases (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Operating Lease, Expense	$ 77,000	$ 73,000
Operating Lease, Weighted Average Remaining Lease Term (Year)	2 years 7 months 6 days
Operating Lease, Weighted Average Discount Rate, Percent	6.00%
Cost of Sales [Member]
Operating Lease, Expense	$ 49,000	46,000
General and Administrative Expense [Member]
Operating Lease, Expense	$ 28,000	$ 27,000

Note 8 - Leases - Future Operat

Note 8 - Leases - Future Operating Lease Payments and Lease Liability (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Jun. 30, 2021
2022 (remaining nine months)	$ 219
2023	292
2024	264
Total	775
Less: imputed interest	(60)
Total lease liability	715
Less current portion	(256)	$ (252)
Non-current lease liability	$ 459	$ 524

Note 9 - Contracts With Custo_3

Note 9 - Contracts With Customers (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Geographic Distribution, Foreign [Member]
Revenue from Contract with Customer, Excluding Assessed Tax, Total	$ 0
Prostate Brachytherapy [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member]
Concentration Risk, Percentage	77.00%	79.00%
Product and Service, Other [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member]
Concentration Risk, Percentage	23.00%	21.00%

Note 9 - Contracts With Custo_4

Note 9 - Contracts With Customers - Concentration of Customers (Details) - Revenue Benchmark [Member] - Customer Concentration Risk [Member]	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
El Camino, Los Gatos, & Other Facilities [Member]
Concentration risk	28.50%	25.70%
GT Medical Technologies, Inc. [Member]
Concentration risk	15.00%